Brain targeted low molecular weight hydrophobic anti oxidant compounds

Abstract

Novel brain targeted low molecular weight, hydrophobic antioxidants and use of antioxidants in treatment of central nervous system neurodegenerative disorders such as Parkinson's, Alzheimer's and Creutzfeldt-Jakob's diseases and in treatment of conditions of peripheral tissues, such as acute respiratory distress syndrome, amyotrophic lateral sclerosis, atheroscierotic cardiovascular disease and multiple organ dysfunction, in which oxidants are overproduced.

What is claimed is:  
     
         1 . A method of reducing oxidative stress in the brain of an organism having a blood brain barrier, the method comprising administering an amide compound to the organism, said compound having: 
 (a) a combination of molecular weight and membrane miscibility properties for permitting said compound to cross the blood brain barrier of the organism;    (b) a sulfhydril group for exerting antioxidation properties; and    (c) a chemical make-up for permitting said compound or its intracellular derivative to accumulate within the cytoplasm of cells.    
     
     
         2 . The method of  claim 1 , wherein said administration is systemic.  
     
     
         3 . The method of  claim 1 , wherein said organism is a human being.  
     
     
         4 . The method of claim  claim 1 , wherein the oxidative stress in the brain is a pathology caused by a neurodegenerative disorder.  
     
     
         5 . The method as in  claim 4 , wherein said neurodegenerative disorder is selected from the group consisting of Parkinson's disease, Alzheimer's disease, basal ganglia degenerative diseases, motoneuron diseases, Scrapie, spongyform encephalopathy and Creutzfeldt-Jakob's disease.  
     
     
         6 . The method as in  claim 4 , wherein the amide compound is selected from the group consisting of:  
       
         
           
           
               
               
           
         
       
     
     
         7 . A method of reducing oxidative stress in a tissue of an organism, the method comprising administering an amide compound to the organism, the amide compound is selected from the group consisting of:  
       
         
           
           
               
               
           
         
       
     
     
         8 . The method of  claim 7 , wherein said organism is a human being suffering from a condition associated with over production of oxidants.  
     
     
         9 . The method of  claim 8 , wherein said condition is selected from the group consisting of acute respiratory distress syndrome, amyotrophic lateral sclerosis, atheroscierotic cardiovascular disease, multiple organ dysfunction, Parkinson's disease, Alzheimer's disease, basal ganglia degenerative diseases, motoneuron diseases, Scrapie, spongyform encephalopathy and Creutzfeldt-Jakob's disease.